Indication
Treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.
Loading your page…
Loading your page…
Hemophilia B
Marketing Authorisation Holder: CSL Behring GmbH
EMA Authorisation: 20/02/2023
INN: etranacogene dezaparvovec
AI Drug & Interaction Analysis
Free account required
Ask Osler about Hemgenix: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.